Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Analyst consensus: Nineteen analysts give Arvinas an average "Hold" rating (2 sell, 7 hold, 10 buy) with a 12‑month average price target of $13.88.
• Quarterly results missed expectations: Arvinas reported ($1.10) EPS vs. ($0.55) expected and revenue of $9.5M vs. $37.26M expected, an 84% year‑over‑year revenue decline.
• Insider and institutional activity: Director Briggs Morrison purchased 20,000 shares at $13.40 (boosting his stake ~26.3%) while insiders sold 63,864 shares over 90 days, and institutions/hedge funds own about 95% of the stock.

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) has been given an average rating of "Hold" by the nineteen research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $13.8824.

Several research analysts have weighed in on the stock. Truist Financial set a $10.00 price objective on shares of Arvinas in a report on Wednesday, March 18th. Wedbush raised their price objective on shares of Arvinas from $9.00 to $11.00 and gave the stock a "neutral" rating in a report on Tuesday, February 24th. Piper Sandler reissued an "overweight" rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Barclays raised their price objective on shares of Arvinas from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, December 17th. Finally, Wall Street Zen lowered shares of Arvinas from a "hold" rating to a "sell" rating in a report on Monday, March 2nd.

Insider Activity at Arvinas

In other Arvinas news, Director Briggs Morrison purchased 20,000 shares of the firm's stock in a transaction dated Friday, March 6th. The stock was acquired at an average cost of $13.40 per share, with a total value of $268,000.00. Following the acquisition, the director owned 96,021 shares of the company's stock, valued at approximately $1,286,681.40. This represents a 26.31% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director John G. Houston sold 35,297 shares of Arvinas stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $13.21, for a total transaction of $466,273.37. Following the completion of the transaction, the director directly owned 1,122,183 shares of the company's stock, valued at $14,824,037.43. This trade represents a 3.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 63,864 shares of company stock worth $802,443 over the last 90 days. Company insiders own 4.73% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Hsbc Holdings PLC boosted its holdings in shares of Arvinas by 18.8% in the 4th quarter. Hsbc Holdings PLC now owns 73,779 shares of the company's stock valued at $876,000 after buying an additional 11,672 shares during the period. Corient Private Wealth LLC acquired a new position in shares of Arvinas in the 4th quarter valued at about $127,000. Invesco Ltd. boosted its holdings in shares of Arvinas by 26.9% in the 4th quarter. Invesco Ltd. now owns 302,100 shares of the company's stock valued at $3,583,000 after buying an additional 64,044 shares during the period. State of Tennessee Department of Treasury acquired a new position in shares of Arvinas in the 4th quarter valued at about $323,000. Finally, Ikarian Capital LLC boosted its holdings in shares of Arvinas by 58.3% in the 4th quarter. Ikarian Capital LLC now owns 358,257 shares of the company's stock valued at $4,249,000 after buying an additional 132,000 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Price Performance

Shares of ARVN stock opened at $10.97 on Thursday. The firm has a market cap of $701.64 million, a P/E ratio of -8.57 and a beta of 1.97. Arvinas has a 1-year low of $5.90 and a 1-year high of $14.51. The firm has a fifty day moving average of $11.98 and a two-hundred day moving average of $11.56.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.55). The company had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.Arvinas's revenue was down 84.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.63) earnings per share. On average, sell-side analysts expect that Arvinas will post -3.81 EPS for the current year.

About Arvinas

Arvinas, Inc NASDAQ: ARVN is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.

The company's most advanced clinical candidates address hormone-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.